Good opportunities in a pressured sector

Hitting the trough

Q2e: sector cheap, but less H2 optimism

Strong cash flow around the corner

Analyst Day: On track for '27 targets, but cautious on AI

Norwegian banks: Q1'25 outcome vs. expectations

Nordic non-life insurance – Q1 reporting wrap

Avanza Bank Holding AB: 2 directors

Two Directors at Avanza Bank Holding AB bought 784 shares at between 327.400SEK and 339.000SEK. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

Decent player activity in Q2 to date

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Post-Q1: rising fear creates opportunities

SpareBank 1 Sør-Norge (Hold, TP: NOK180.00) - Strong core revenues

Helped by strong core revenues and limited loan losses, the Q1 ROE was 13.5%, despite some underlying cost inflation and merger-related costs. Backed by solid earnings generation, the CET1 ratio rose ~30bp QOQ to 18.3%, with an ample buffer to the ~17.6% requirement, boding well for meaningful distributions over our forecast horizon. We have raised our 2026–2027e EPS by 2–3% on higher NII and fee income, and our target price to NOK180 (170), but continue to find the valuation fair and reiterate ...

Strong numbers, but pricing is fair

Early Q2 players up 1% vs Q1

Strong adj. PBLL beat +8% vs. cons

Adj. PBLL +3% vs ABGSCe, and +8% vs. cons; Stronger lending growth and unchanged synergies guidance; Expect cons. adj. EPS up by 2-4% and stock to go 2-5% today

Evolution (Buy, TP: SEK1100.00) - Play it right in fencing

Despite intact 2025 EBITDA margin guidance, a soft Q1 and near-term uncertainties made us cut our 2025–2027e EPS by c10%. The step-up of focus on regulated markets supports the long-term case, although it comes with costs near-term. We reiterate our BUY but have cut our target price to SEK1,100 (1,440). We expect buybacks, expansion, new games, and growth improvements to strengthen the story later in 2025.

Big Q1 disappointment, but exaggerated reaction

Big sales miss, concerning growth numbers

Heads-up for report 30 April

In-line report a relief